Dr. Neil Vasdev
Dr. Neil Vasdev received Bachelor’s degrees (summa cum laude, Hon. B.Sc. Chemistry & B.A. Psychology), followed by a Ph.D. (chemistry) from McMaster University. Prior to starting graduate school he worked in industry as a chemist at Astra Pharma and Glaxo Wellcome, as well as at a radiopharmacy. Following a postdoctoral fellowship in radiochemistry at Berkeley National Labs, he joined the faculty at the University of Toronto (2004-2011). He was the Director of Radiochemistry at Massachusetts General Hospital (2011-2017), and he still maintains his faculty appointment at Harvard Medical School.
He recently returned to Canada as the inaugural Director of the Azrieli Centre for Neuro-Radiochemistry, at CAMH. He serves as the Associate Director and Chief Radiochemist of the CAMH Research Imaging Centre. He is also the endowed Azrieli Chair in Brain and Behaviour, and a Tier 1 Canada Research Chair in Radiochemistry and Nuclear Medicine. In addition, he is a full Professor in the Department of Psychiatry at the University of Toronto.
Several of the radiotracers developed by his laboratory are in preclinical use worldwide, and many of these compounds have been used for first-in-human neuroimaging studies. Dr. Vasdev has published more than 100 peer-reviewed articles, and he has received numerous scholarly awards throughout his career.
Dr. Lee Josephson
Dr. Lee Josephson received a B.S. from the University of Wisconsin (Chemistry) and a Ph.D. from the State University of New York at Stony Brook (Chemical Biology).
He then did a post-doctoral fellowship at Harvard University under Dr. Guido Guidotti and was a cofounder of AMAG Pharmaceuticals (AMAG, AMEX). There he served as Chief Scientific Officer and lead the development of FDA approved magnetic nanoparticle MR contrast agents.
He joined the Massachusetts General Hospital in 1997 and was a Co-founder of T2 Biosystems (TTOO, NASDAQ).
Dr. Josephson’s research interests include the design of radioactive, magnetic and fluorescent imaging probes and the use of magnetic nanoparticles and NMR detectors for in vitro clinical assays.
He has published over 100 peer-reviewed papers and is a co-inventor on more than 35 issued US patents. He is an Associate Professor in the Department of Radiology at Harvard Medical School.
Dr. Jack Hoppin
Dr. Jack Hoppin is the Co-founder and Managing Director of inviCRO, a leading provider of imaging services, software solutions, and advanced data analysis in research and drug development. inviCRO employs ca. 100 research scientists representing a broad array of disciplines from both laboratory and computational research. Dr. Hoppin brings 20 years of experience in the medical imaging research community to inviCRO, which has been included on Inc Magazine’s 500|5000 list of fastest-growing privately owned US companies for two consecutive years.
Before co-founding inviCRO in 2008, Dr. Hoppin served as the VP of Imaging Systems at Bioscan, Inc., worked as an Alexander von Humboldt post-doctoral fellow at the Forschungszentrum Jülich, Germany, and received his PhD in applied mathematics in 2003 from the University of Arizona.
Dr. Hoppin sits on multiple boards and committees including the Board of Trustees for the World Molecular Imaging Society.